US EditionPublished • loading... • Updated
OrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
OrsoBio obesity data; Monte Rosa's prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide, OrsoBio’s oral obesity drug TLC-6740 led to an additional ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
